Currently, a phase 1/2 clinical trial evaluating Pinometostat in combination with standard chemotherapy to treat both child and adult patients with newly diagnosed MLL-rearranged leukemia is ongoing (NCT03724084) (Table 1). The gene discussed is KMT2A; the disease is leukemia.